Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa

Virology

Volumn 318, Issue 2, 2004, Pages 507-515

  Milligan, Gregg N ^a   Dudley McClain, Kristen L ^b   Chu, Chin Fun ^a   Young, Christal G ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

Genital tract; Herpes simplex virus; Sensory ganglia; T lymphocyte

Indexed keywords

THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENITAL TRACT INFECTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; MOUSE; NONHUMAN; NOSE MUCOSA; PASSIVE TRANSPORT; PRIORITY JOURNAL; SENSORY GANGLION; T LYMPHOCYTE;

HERPES; HUMAN HERPESVIRUS 2;

EID: 1242328735     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2003.10.010     Document Type: Article

References (35)

1. Balachandran N., Bacchetti S., Rawls W.E. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect. Immun. 37:1982;1132.
2. Bourne N., Milligan G.N., Schleiss M.R., Bernstein D.I., Stanberry L.R. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine. 14:1996;1230.
3. Brockman M.A., Knipe D.M. Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J. Virol. 76:2002;3678.
4. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas J.M. Jr., Handsfield H.H., Warren T., Marr L., Tyring S., DiCarlo R., Adimora A.A., Leone P., Dekker C.L., Burke R.L., Leong W.P., Straus S.E. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV vaccine study group. JAMA. 282:1999;331.
5. Dudley K.L., Bourne N., Milligan G.N. Immune protection against HSV-2 in B-cell-deficient mice. Virology. 270:2000;454.
6. Eo S.K., Gierynska M., Kamar A.A., Rouse B.T. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J. Immunol. 166:2001;5473.
7. Erlich K.S., Dix R.D., Mills J. Prevention and treatment of experimental herpes simplex virus encephalitis with human immune serum globulin. Antimicrob. Agents Chemother. 31:1987;1006.
8. Gallichan W.S., Rosenthal K.L. Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract. Virology. 224:1996;487.
9. Gallichan W.S., Rosenthal K.L. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J. Infect. Dis. 177:1998;1155.
10. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., Rosenthal K.L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166:2001;3451.
11. Gierynska M., Kumaraguru U., Eo S., Lee S., Krieg A., Rouse B.T. Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J. Virol. 76:2002;6568.
12. Holmberg S.D., Stewart J.A., Gerber A.R., Byers R.H., Lee F.K., O'Malley P.M., Nahmias A.J. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA. 259:1988;1048.
13. Hopkins S., Kraehenbuh J.P., Schodel F., Potts A., Peterson D., deGrandi P., Nardelli-Haefliger D. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect. Immun. 63:1995;3279.
14. Kitamura D., Roes R., Kuhn R., Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain gene. Nature. 350:1991;423.
15. Koelle D.M., Schomogyi M., Corey L. Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection. J. Infect. Dis. 182:2000;662.
16. Kuklin N., Daheshia M., Karem K., Manickan E., Rouse B.T. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J. Virol. 71:1997;3138.
17. Kuklin N.A., Daheshia M., Chun S., Rouse B.T. Role of mucosal immunity in herpes simplex virus infection. J. Immunol. 160:1998;5998.
18. Langenberg A.G., Burke R.L., Adair S.F., Sekulovich R., Tigges M., Dekker C.L., Corey L. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and efficacy. Ann. Intern. Med. 122:1995;889.
19. Langenberg A.G., Corey L., Ashley R.L., Leong W.P., Straus S.E. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV vaccine study group. N. Engl. J. Med. 341:1999;1432.
20. McDermott M.R., Smiley J.R., Leslie P., Brais J., Rudzroga H.E., Bienenstock J. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J. Virol. 51:1984;747.
21. Mestecky J., Abraham R., Ogra P.L. Common mucosal immune system and strategies for the development of vaccines effective at the mucosal surfaces. Ogra P.L., Mestecky J., Lamm M.E., Strober W., McGhee J.R., Bienenstock J. Handbook of Mucosal Immunology. 1994;357 Academic Press, San Diego, CA.
22. Milligan G.N. Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2. J. Virol. 73:1999;6380.
23. Milligan G.N., Bernstein D.I. Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology. 206:1995;234.
24. Milligan G.N., Bernstein D.I. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology. 212:1995;481.
25. Milligan G.N., Bernstein D.I., Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 160:1998;6093.
26. Morrison L.A., Da Costa X.J., Knipe D.M. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology. 243:1998;178.
27. Morrison L.A., Zhu L., Thebeau L.G. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J. Virol. 75:2001;1195.
28. Openshaw H., Shavrina S.L.V., Wohlenberg C., Sekizawa T., Notkins A.L. Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation. J. Gen. Virol. 44:1979;205.
29. Parr E.L., Parr M.B. Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2. Immunology. 98:1999;639.
30. Parr E.L., Bozzola J.J., Parr M.B. Immunity to vaginal infection by herpes simplex virus type 2 in adult mice: characterization of the immunoglobulins in vaginal mucus. J. Reprod. Immunol. 38:1998;15.
31. Rudin A., Johansson E.L., Bergquist C., Holmgren J. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect. Immun. 66:1998;3390.
32. Sin J., Kim J.J., Pachuk C., Satischandran C., Weiner D.B. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4 (+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J. Virol. 74:2000;11173.
33. Smith J.S., Herrero R., Bosetti C., Munoz N., Bosch F.X., Eluf-Neto J., Castellsague X., Meijer C.J.L.M., Van den Brule A.J.C., Franceschi S., Ashley R. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J. Natl. Cancer Inst. 94:2002;1604.
34. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., Tyring S., Aoki F.Y., Slaoui M., Denis M., Vandepapeliere P., Dubin G. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:2002;1652.
35. Wasserheit J.N. Epidemiological synergy: interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex. Transm. Dis. 19:1992;61.